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Abstract
Objective The aim was to create pathological changes in
mice relevant to human smoke exposure that can be used to
further understand the mechanisms and pathology of
smoke-induced inﬂammatory disease.
Methods Mice were exposed to tobacco smoke or lipo-
polysaccharide (LPS) to generate an inﬂammatory inﬁltrate
within the lungs.
Results Tobacco smoke exposure over a 4 day period led
to neutrophilia in the lungs of BALB/c mice. Within the
inﬂammatory exudates, signiﬁcant changes were also seen
in protein levels of IL-1B, IL-6, MIP-2, KC (IL-8) and
TIMP-1 as measured by ELISA. Further protein changes,
as measured via multiplex analysis revealed increased
levels of MMP-9, MDC, LIF and MCP-1, amongst other
mediators. Major changes in whole lung tissue gene
expression patterns were observed. The neutrophilia seen
after smoke exposure was steroid-insensitive, relative to
doses of steroid needed to reduce LPS-driven neutrophilia
in controls. This exposes pathological switches that are
changed upon exposure to tobacco smoke, rendering ste-
roids less effective under these conditions. Challenge of
chemokine receptor type 1 (CCR1) KO mice in the tobacco
smoke model showed that lack of this gene protected the
mice from smoke-induced inﬂammation.
Conclusions This suggests the CCR1 receptor has a key
role in the pathogenesis of smoke-induced inﬂammation.
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Tobacco smoke induced inﬂammation  Steroid 
C chemokine receptor 1
Abbreviations
BAL Bronchoalveolar lavage
CCR1 Chemokine receptor type 1
ELISA Enzyme linked immune sorbent assay
IL-1 Interleukin 1
IL-6 Interleukin 6
IL-8 Interleukin 8
KC Keratinocyte chemoattractant
KO Knock out
FP Fluticasone propionate
LIF Leukemia inhibitory factor
MCP-3 Monocyte-speciﬁc chemokine 3
MIP-1 Macrophage inﬂammatory protein 1
MIP-2 Macrophage inﬂammatory protein 2
MMP-9 Matrix metalloproteinase 9
RSV Respiratory syncytial virus
TIMP1 Tissue inhibitors of metalloproteinase 1
TNF Tumour necrosis factor
TS Tobacco smoke
Introduction
Chronic obstructive pulmonary disease (COPD) is a major
cause of death and morbidity in the Western world [1]. It is
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leading cause of death in the world. COPD is increasing in
developing countries [2]. The main causative agent in
COPD is cigarette smoke [3]. In addition, a genetic com-
ponent is involved in the development of COPD [4].
Treatments for COPD include both inhaled corticosteroids
(ICS), Beta2 agonists, muscarinic receptor antagonists and
combinations of these agents [5].
We have established a mouse model of inﬂammation
which is triggered by tobacco smoke. This model is being
used to understand the link between pathological events in
the inﬂammatory model and human disease. The model can
be used to test target mechanisms for use as potential new
anti-inﬂammatory treatments and to understand the phar-
macology of the inhibitors of such mechanisms. We have
assessed the activity of steroids in the model and found
steroids to be relatively inactive in comparison to steroid
activity in a separate lipopolysaccharide (LPS) driven
inﬂammatory model. Finally, we show the effects of CCR1
transgenic (KO) mice on the inﬂammatory response.
The model we describe is a new robust model and for an
in vivo application is of reasonably high throughput. We
hope the model can serve as a platform for the testing of
other mechanisms and hypotheses to further understand the
pathobiology of cigarette smoke-induced inﬂammation.
This could also include the addition of other components to
the protocol; such studies have already been carried out
with the addition of bacteria to a 4 day smoke exposure [6].
Materials and methods
Animals
Female BALB/c mice (weighing 18–22 g) were purchased
from Taconic Europe A/S (Denmark), housed 4–6 per cage
and allowed to acclimatize for 1 week before experiments.
Animals were provided with food, R70 pellets (Lantma ¨nnen,
Sweden), and water ad libidum. Their body weights were
measured prior to ﬁrst exposure and termination.
CCR1 KO mice (weighing 18–22 g) backcrossed to
C57BL/6 for ten generations were bought from the Chil-
dren’s Medical Center Corporation, Boston, MA, USA.
Age matched C57BL/6 mice were used as controls. Female
mice were used in all experiments.
Animals were handled in conformity with standards
established by Council of Europe ETS123 AppA, Swedish
legislation and AstraZeneca global internal standards.
Tobacco smoke exposure
Mice were exposed to cigarette smoke using a whole
body smoke exposure unit SIU48 (PromechLab AB,
Vintrie, Sweden). Up to 64 mice were placed in a sealed
exposure chamber, divided into separate chambers and
exposed to mainstream tobacco smoke or room air
(control mice). Smoke was generated from 1R3F
research cigarettes (Tobacco and Health Research Insti-
tute, University of Kentucky) with ﬁlters removed.
Smoke was drawn into the box with a vacuum ﬂow that
was aligned to 16 puffs per cigarette. Air was drawn into
the box after each puff, and the control unit automati-
cally cycled the opening and closing of air and smoke
inlets (5 sec air and 10 sec smoke). Side stream smoke
was removed via exhaust. Animals were exposed to 12
cigarettes, twice daily, for 1, 2, 3, 4, or 9 days. There
was a 5 h interval between the exposures. The SIU48
allows for monitoring of smoke input in real time to
ensure consistency between exposures. Terminations and
analysis were carried out in each case 16 h after the last
smoke exposure.
The exposure system and methods are identical to that
already described and published in Gashler et al. [6].
Cotinine levels were measured by ELISA (Bio-Quant, San
Diego, CA, USA) in the blood of mice after 4 days of
smoke exposure. In all mice levels of cotinine were
approximately 350 ng/ml. In addition, carboxyhaemoglo-
bin levels were measured by spectrometry and were
approximately 7% after smoke exposure.
LPS exposure
Female BALB/c mice (weighing 18–22 g) were used.
Nonanaesthetised mice were placed into a ventilated
chamber, that was directly connected to a Pari LC
 JetStar
nebuliser (PARI Respiratory Equipment, Inc., Midlothian,
VA, USA), and exposed either to 1 mg/ml P. aeruginosa-
derived LPS (L9143, Sigma-Aldrich) or to the vehicle
(0.9% NaCl) for 10 min.
Bronchoalveolar lavage
Mice were anaesthetised by an interperotineal (i.p.) injec-
tion of sodium pentobarbital (60 mg/kg) either 16 h after
the last smoke exposure or 24 h after LPS challenge. After
semi-excision of the trachea, a plastic catheter was inser-
ted, and the bronchoalveolar lavage (BAL) ﬂuid was
collected by passive/gravity ﬂow of phosphate buffered
saline (PBS) (2 ml 9 2 times; a 2 ml syringe placed at
23 cm height) into the lungs. Retrieved ﬂuid, kept on ice at
4C from both washes was pooled and centrifuged
(1,200 rpm 9 10 min, 4C). The supernatant was ali-
quoted and saved at -70C for mediator analysis; the cell
pellet was resuspended in 0.25 ml PBS and maintained at
4C until cell determination.
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Total cell number in BAL was determined using a semi
automatic cell counter Sysmex F-800. Differential cell
counts were performed using standard morphological cri-
teria on May-Gru ¨nwald and Giemsa (Merck) stained
cytospins (50,000 cells/slide, 500 rpm 9 3 min, Shandon
CytoSpin 3 cytocentrifuge). At least 200 cells were counted
per cytospin. Leukocyte numbers were determined by
multiplying the percentage of each leukocyte subpopula-
tion with the total number of cells for each sample and
expressed as cell number/sample.
Mediator measurements and multiplex analysis
Mediators (KC, MIP-1a, MIP-2, IL-1b, IL-6, TIMP-1)
were determined using ELISA kits (R&D System, USA)
according to the manufacturer’s instructions. In some
studies BAL ﬂuid samples were sent to Rules Based
Medicine (Texas, USA) for multiplex analysis.
Treatment with compounds
The mice were anaesthetised with an isoﬂurane mixture
(N2O: O2; 1.2:1.4 and 4% isoﬂurane), put in a supine
position with 30–40 angle and intratracheally (i.t.)
instilled either with vehicle or ﬂuticasone propionate (FP)
in a volume of 1 ml/kg 1 h prior to LPS or tobacco smoke
exposure. The topical instillations were performed using a
modiﬁed metal cannula with a bulb-formed top.
Statistical analysis
Data are expressed as mean ± SEM. Statistical analysis
was performed using Student’s t test for samples with
unequal variances. P values \0.05 were considered as
statistically signiﬁcant.
Gene expression analysis
Expression levels of more than 39,000 transcripts were
measured in whole lung tissue from mice exposed to fresh
air (n = 10) or cigarette smoke (n = 10) using Affymetrix
GeneChip
 Mouse Expression Arrays 430A and 430B
(Affymetrix, Santa Clara, CA, USA). Whole lung tissue
was homogenized using a dismembrator (Mikro-Dismem-
brator U, B. Braun Biotech International, PA, USA) and
RNA isolated according to the TRIzol
 protocol (Invitro-
gen, Carlsbad, CA, USA) with an additional puriﬁcation
using RNeasy columns (Qiagen, Hilden, Germany). Total
RNA was measured spectrophotometrically and the quality
assessed by visualization of ribosomal RNA bands on 1%
agarose gels. Ten micrograms of total RNA from each
sample was used to generate hybridisation probes accord-
ing to the Affymetrix GeneChip Expression Analysis
Technical Manual (Affymetrix). Double-stranded cDNA
was synthesised (Invitrogen) and subsequently in vitro
transcribed in the presence of biotinylated nucleotides
using an Enzo BioArray
TM HighYield
TM RNA Transcript
Labelling Kit (Enzo Life Sciences, Inc., Farmingdale, NY,
USA). Fifteen micrograms of fragmented cRNA were
hybridised to each array. Hybridisation, washing and
staining of the arrays were performed according to the
instructions provided by Affymetrix. The GCOS software
from Affymetrix was used to generate transcript expression
level values, signals, and corresponding present call values
as measures of the certainty of detection. Group compari-
sons between the fresh air and cigarette smoke treated
groups were made using a modiﬁed t test, Samroc [7] and
overall differences between samples analysed with Principal
Component Analysis in SIMCA-P ? (Umetrics AB, Umea ˚,
Sweden) and visualised in Spotﬁre
 DecisionSite
 (TIBCO
Spotﬁre Inc., Gothenburg, Sweden).
Results
Tobacco smoke exposure results in an inﬂammatory
cell based inﬂux
The whole body smoke exposure system was developed
in collaboration with ProMech (Malmo ¨, Sweden) and
enables the exposure of up to 60 animals at a time. The
smoke exposure was carried out within a sealed unit
where the animals were placed and were free to move.
The smoke was allowed to ﬂow through the cabinet and
there was a continual ﬂow of air through the exposure
area. The smoke exposure system is identical to the one
used in a previous publication [6]. The same system was
used for air-exposed control animals but no tobacco
smoke was in the chamber.
Exposure for 50 min two times a day produced a robust
cell inﬂux as measured in the BAL (Fig. 1). Cell inﬂux
peaked at day 4, although inﬂammation was also observed
when animals were exposed for 9 days. The inﬂammatory
cell inﬂux was dominated by neutrophils. Other cell types
were seen in the BAL in smaller numbers, including
macrophages. Experiments where animals were exposed
only once per day produced little inﬂammation (data not
shown).
Airway inﬂammation is characterised by a range
of inﬂammatory mediators
Cytokine mediators were measured in the BAL and these
were correlated with the inﬂammatory cell inﬂux (Fig. 2).
The role of the CCR1 receptor 819The levels of KC peaked before the peak of inﬂammatory
neutrophils. Further temporal analysis of mediator levels
versus neutrophilia also showed the presence of IL-1b,I L - 6 ,
MIP-1a, MIP-2, and TIMP-1 with respect to time. IL-1b
levels and MIP-1a levels peaked at the same time as neu-
trophil levels (Fig. 2). Using Rules Based Medicine’s
analysis, we further characterised the protein inﬁltrate and
saw that a number of mediators increased in the BAL
following TS exposure. Proteins showing the most increase
in presence in the BAL included MMP-9, TIMP-1, MCP-1
and MIP-1 (Table 1). At no time point could any TNFa
levels be detected within the BAL.
After TS exposure substantial changes in the expression
of genes within the lung are observed
Gene expression changes in the lung were determined
using Affymetrix GeneChip
 microarrays. TS treatment
caused an increase of 685 probe sets and a decrease of 586
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Fig. 1 Cellular inﬁltrate in BAL following TS exposure. BALB/c
mice (groups of 8) were exposed to either air or TS twice a day for
50 min for 1, 2, 3, 4, or 9 days, then were terminated and cells
counted from BAL. Total cells are shown (black columns) and
neutrophils (grey columns) and macrophages (clear columns). Statis-
tically signiﬁcant differences in response to air controls are shown
*P\0.05, **P\0.01, ***P\0.001. The data for the air control
groups for each day have been pooled and shown as ‘‘air’’
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Fig. 2 Time course of inﬂammatory inﬁltration into BAL. BALB/c
mice (groups of 8) were exposed to TS for between 1 and 9 days for
50 min, twice a day. Red columns show the presence of neutrophils at
the various time points (which are identical a–f). The lines show the
presence of cytokines present within the BAL at various time points.
Statistically signiﬁcant differences in response to air controls are
shown *P\0.05, **P\0.01, ***P\0.001. The different cyto-
kines measured are as follows: a KC, b MIP-2, c MIP-1a, d TIMP-1,
e IL6, f IL-1 beta
820 P.-O. O ¨nnervik et al.probe sets out of 20,344 probe sets detected in at least 20%
of the samples, using a group comparison P value below
0.001 as cut-off. Among the most highly upregulated genes
after TS treatment were the acute phase protein serum
amyloid A-3, Saa3 (279 increase, P value = 0.000004),
chemokine (C-X-C motif) ligand 5, CXCL5 (269 increase,
P value = 0.0002), NADPH oxidase organiser 1, Noxo1
(259 increase, P value = 0.00001) and matrix metallo-
peptidase 12, MMP-12 (109 increase, P value = 0.00001).
Changes in BAL ﬂuid protein levels for IL-1b, KC, MCP-1,
MMP-9andTIMP-1werealsoseenatthetranscriptionallevel
in whole lungs (Table 1).
Response to TS is insensitive to steroids relative to an
LPS model
We wished to compare the sensitivity of the inﬂammatory
response to TS with another inﬂammatory model, so we
also used an LPS mouse model to generate a BAL speciﬁc
neutrophilia (Fig. 3b). We included groups that had been
exposed to LPS and treated with different concentrations of
a steroid, FP. It can be seen that FP was able to signiﬁ-
cantly reduce the LPS-driven inﬂammation. We carried out
an analogous experiment in the TS-driven inﬂammatory
model (Fig. 3b). Here, even though the same doses of FP
were used, no signiﬁcant inhibition of the TS-driven neu-
trophilia could be observed. No other cell types were
signiﬁcantly inhibited by treatment with FP (Fig. 3a). In
addition, it can be seen that the levels of neutrophilia in the
BAL were lower in the TS-driven system than in the LPS-
driven model, and still no signiﬁcant inhibition with FP
could be observed.
Table 1 Gene expression and mediator changes within BAL
Mediator mRNA ratio smoke/air Protein ratio smoke/air
IL-1b 1.9*** 2.9***
KC 10*** 5.0**
MCP-1 5.5*** 9.7***
MMP-9 1.2* 7.1*
TIMP-1 5.3*** 16*
IL-1b, KC, MCP-1, MMP-9 and TIMP-1 mRNA and protein levels in
samples from cigarette smoke treated animals (tobacco smoke for
4 days) relative to samples from animals receiving fresh air (air for
4 days)
*P\0.05; **P\0.01; ***P\0.001
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Fig. 3 Sensitivity of tobacco smoke model to steroids relative to an
analogous LPS model. a Sensitivity of the TS-induced inﬂammation
to steroids. Four groups of BALB/c mice (8 mice per group) were
exposed to air, tobacco smoke, tobacco smoke plus 30 lg/kg of FP,
tobacco smoke plus 300 lg/kg FP. The cellular response in BAL is
shown, reﬂecting total cells, macrophages and neutrophils. Statisti-
cally signiﬁcant differences between groups are shown as *P\0.05,
**P\0.01, ***P\0.001. b Sensitivity of LPS-induced inﬂamma-
tion to steroids. Four groups of BALB/c mice (8 mice per group) were
exposed to air, LPS, LPS plus 30 lg/kg of FP, LPS plus 300 lg/kg
FP. The cellular response in BAL is shown, reﬂecting total cells,
macrophages and neutrophils. Statistically signiﬁcant differences
between groups are shown as *P\0.05, **P\0.01, ***P\0.001
The role of the CCR1 receptor 821Mice lacking the CCR1 receptor have a reduced
inﬂammatory response to TS
We wished to further characterise the acute tobacco smoke
model. Given we observed the CCR1 ligand MIP-1a in the
BAL of animals after tobacco smoke exposure, we inves-
tigated the role of the MIP1a receptor, CCR1, in the
tobacco smoke model. We carried out a 4 day TS exposure
on mice lacking the CCR1 gene (CCR1 Knock out) and
compared this to wild type mice. It can be seen that the
inﬂammatory response to TS is dramatically reduced in the
CCR1 KO mice. This is observed by a reduction in neu-
trophils in the BAL (Fig. 4) as well as a reduction in IL-1B
and MIP-1a in the BAL (Fig. 4). The levels of KC in the
CCR1 KO animals were not reduced but, in fact, elevated
in the BAL of the transgenic mice.
Discussion
Novel anti-inﬂammatories are sought for the treatment of
COPD. Mouse models are being increasingly used to
understand smoke-induced inﬂammation [8] and are used
within the pharmaceutical industry to support drug dis-
covery programs. Many tobacco smoke models are run as
chronic models, often with changes in lung structure
measured by mean linear intercept of airspaces (for
reviews, see [9, 10]).
There are far fewer acute models of cigarette exposure,
and it was our intention to develop a new acute model of
TS-driven inﬂammation with some characteristics of
smoke-induced inﬂammation in humans. We also think that
the steroid insensitivity of the model is key and that
compounds showing greater efﬁcacy in the tobacco smoke
model than steroids have a greater chance of efﬁcacy in
human clinical trials. The model is also of reasonable
throughput and can be used for the medium throughput
evaluation of candidate drugs for novel anti-inﬂammato-
ries. In addition, we see it as a valuable platform for adding
in extra factors to augment the effects of TS and for further
understanding the pathobiology of smoke-induced
inﬂammation.
Leclerc et al. [11] describe an acute TS model in which
mice were exposed to TS for 3 days and a neutrophil-
dominated response was seen, although this was
also accompanied by signiﬁcant eosinophilia. A full
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Fig. 4 Effects of deletion of the gene for the CCR1 receptor on TS-
induced inﬂammation. Wild type female C57/BL76 mice (8 per
group) or female CCR1 transgenic C57/BL76 mice (8 per group)
were exposed to TS for 4 days for 50 min twice a day. Control groups
were included that were exposed only to air. After 4 days the animals
were terminated and the following determined. a Total cells within
the BAL, b macrophages within the BAL, c neutrophil levels, d KC
levels, e MIP-1 levels and f IL-1 beta levels. Air controls are shown as
clear columns and smoke exposed groups as red columns. Statistically
signiﬁcant differences between groups are shown as *P\0.05,
**P\0.01, ***P\0.001
822 P.-O. O ¨nnervik et al.characterisation of the inﬂammatory response was not
done. However, KC, MIP-1 and MIP-2 were shown to be
upregulated in the BAL. The model also showed a degree
of steroid insensitivity, however the steroid tested was
dexamethasone. In the present study, we used the much
more potent steroid FP (versus the glucocorticoid receptor)
[12]. In addition, at the highest concentration of dexa-
methasone tested, inﬂammation was reduced in the model
described by Leclerc [11]. Medicherla et al. [13] have also
described a tobacco smoke model. There, mice were
exposed for 5 or 11 days and, in stark contrast to both our
model and the model of Leclerc et al., an inﬂammatory
inﬂux was seen that was dominated by macrophages.
Again, the inﬂammation seen was resistant to dexametha-
sone, but dose levels of only up to 0.3 mg/kg were used.
The differences in inﬂammatory cell population between
the model described by Medicherla et al., and the one
reported here is interesting, but may merely reﬂect that in
Medicherla et al., A/J mice were used, while we used
BALB/c mice. A/J mice lack part of the complement sys-
tem [14] and perhaps would not be able to promote a full
anti-inﬂammatory response to the TS challenge. In fact,
many other studies assessing acute TS exposure in mice
with fully intact complement systems show that acute TS
exposure leads to an inﬂammatory inﬁltrate dominated by
neutrophils [15, 16] and not by macrophages. Although
COPD is a complex disease with a range of cellular and
molecular pathologies, neutrophils are also common in
COPD [17, 18].
In addition, a number of mediators observed speciﬁcally
in the BAL after TS exposure are in common with medi-
ators seen in humans exposed to cigarette smoke. MCP-1 is
involved in the recruitment of monocytes, lymphocytes and
basophils and a member of the CC chemokines [19]. Ele-
vated expression of MCP-1 is seen in COPD [20]. MCP-1
levels also correlate with a decline in lung function in
COPD [21]. Reduction of MCP-1 levels with a therapeutic
antibody in COPD patients also serves to reduce neutrophil
numbers [9]. IL-8, the human equivalent of KC, is also
increased in COPD [22] and this is reﬂected in the BAL
samples from TS exposed animals. From the Rules Based
Medicine analysis we can see that MMP-9 is one of the
proteins highly up-regulated in TS-exposed animals com-
pared to air-exposed animals. MMP-9 has been shown to
be present within COPD lungs [23] and also to increase
within a COPD exacerbation [24]. This could reﬂect the
beginning of a protease/anti-protease imbalance within
the model. The protease/anti-protease balance is one of the
core themes around the pathology of COPD [25] and its
imbalance may also contribute to further damage during a
COPD exacerbation [24].
One interesting omission from the array of mediators
present in the model is the lack of TNFa. TNFa is seen in
the BAL of COPD patients [22]. The lack of TNFa may
represent the mild nature and acute exposure times of the
model. Other acute TS models, also, have not reported
seeing TNFa after acute TS exposure [13, 16], or report no
increase after TS exposure [15].
Gene expression patterns in whole lung tissue following
TS exposure changes dramatically. Many of the changes
seen are related to oxidative stress and this has also been
implicated in COPD [26]. The expression of genes related
to oxidative stress in COPD has been studied in epithelial
cells [27]. Genes involved in proteolytic processing were
also increased. Speciﬁc genes such as Noxo1 were up-
regulated. Noxo1 is a regulator of NADPH oxidase and,
presumably, its up-regulation indicates a response to TS in
trying to control damage via the production of reactive
oxygen species [28], but may subsequently also increase
inﬂammation via the activation of NFkB and MAP kinase
pathways [28]. CXCL5 was up-regulated in the TS exposed
mice after 4 days and has also been shown to be up-reg-
ulated in COPD [29]. MMP-12 is also up-regulated within
COPD patients [30].
Overall, the characterisation of the TS exposed mice
reveals a number of similarities to tobacco smoke exposure
in humans, even after acute exposure. Pharmacological
intervention studies will enable resolution as to which
markers are affected by treatment and thus allow compar-
ison between different anti-inﬂammatory mechanisms.
We feel a key feature of the TS model is that the
inﬂammation observed, as measured by the inﬂux of neu-
trophils to the lung, is relatively steroid insensitive
compared to that seen in an LPS-driven mouse inﬂamma-
tory model (Fig. 3). Although we used Pseudomonas LPS,
the same effects and steroid sensitivity were seen from
experiments with Escherichia coli LPS (data not shown).
We do not think that this insensitivity to steroids is caused
by the ‘‘volume’’ of the inﬂammation. The levels of neu-
trophilia driven by LPS are higher than by TS (Fig. 3). We
hypothesise that the TS exposure triggers molecular
switches in vivo. This switching affects the pharmacolog-
ical intervention by a steroid in the TS model.
Steroids work in COPD but the inﬂammation is not as
well controlled as in asthma [31]. FP is ineffective at
controlling neutrophils in COPD [32] and therefore there is
a pharmacological link between the TS exposure model
and human disease. Interestingly, FP is able to reduce LPS-
driven neutrophilia in humans 6 h after LPS challenge [33],
which again correlates to the ability of FP to reduce LPS-
driven neutrophilia in mice. We are currently assessing
other differences in endpoints between LPS- and TS-driven
models to assess whether further insights can gained for
steroid efﬁcacy in reducing smoke- or LPS-induced
inﬂammation. Also, we will use the TS exposure model in
the future in assessing other pharmacological mechanisms
The role of the CCR1 receptor 823with greater potential than steroids in reducing inﬂamma-
tion provoked by tobacco smoke.
Having established the TS exposure model and charac-
terised it with known agents in respiratory disease, we have
begun to use it to test the rationale for other mechanisms as
potential targets within COPD. One such hypothesis was of
the role of CCR1 in regulating TS-induced inﬂammation;
the CCR1 ligand was observed in the BAL of smoke-
exposed animals. The chemokine receptor CCR1 belongs
to the seven-transmembrane G protein coupled receptor
(GPCR) super-family of receptors and is expressed pri-
marily by T lymphocytes, monocytes/macrophages,
basophils, dendritic cells, eosinophils and neutrophils.
CCR1 deﬁcient mice have been generated, and they show
normal development and leukocyte proﬁles, but signiﬁ-
cantly reduced leukocyte mobilization in response to
different inﬂammatory stimuli [34]. A number of com-
pounds against this receptor are in development for the
treatment of autoimmune/inﬂammatory diseases [35].
Exposure of mice lacking the CCR1 receptor to TS
showed a signiﬁcantly reduced inﬂammatory response
compared to wild type mice. As well as showing a reduced
neutrophil response, the levels of IL-1 and MIP-1a in the
BAL following TS exposure were lower in CCR1 deﬁcient
mice than in wild type controls. This suggests that block-
ade of the CCR1 receptor may be a therapeutic strategy for
the treatment of tobacco smoke-driven inﬂammation. There
is some evidence from human studies to support this
statement. Increased frequency of MIP-1a positive epi-
thelial cells in the bronchial mucosa was observed in
COPD patients, and the frequency of MIP-1a expressing
cells correlated with reduced lung function (FEV1)[ 36].
Key CCR1 ligands (MIP-1a, RANTES and MCP-3) have
been found to be expressed in COPD lung tissue and are
present in BAL or sputum from COPD patients [37].
Within the CCR1 deﬁcient mice study, it was interesting
that after TS exposure the levels of KC, the mouse
homologue of IL-8, were not reduced in the same fashion
as other markers, but in fact were increased after TS
exposure compared to wild type controls. Perhaps this
reﬂects a compensation response, more KC (IL-8) being
produced as a chemotactic factor to try and draw neutro-
phils into the lung. We can also postulate that this means
that there may be other factors, independent of KC (IL-8),
that are responsible for the recruitment of neutrophils into
the lung. This has been suggested for COPD, speciﬁcally
that neutrophils in COPD patients show reduced levels of
migration and chemotaxis in response to IL-8 [38].
Mice insufﬁcient in CCR1 have been analysed previ-
ously in separate model systems. The same transgenic
animals have been used in separate studies published
elsewhere by others. Pancreatitis associated lung injury is
CCR1 dependent [39]. In addition, leukocyte recruitment is
dependent on CCR1 in allergic encephalomyelitis models
[40]. The deletion of CCR1 reduces responses following
RSV infection [41].
In summary, we have developed an acute tobacco smoke-
drivenmousemodelofinﬂammation.Ithasmanysimilarities
to inﬂammation seen in humans exposed to tobacco smoke.
We intend to use the model to further explore the pharma-
cology of TS-induced inﬂammation, to attempt to build the
predictivity of the model for predicting efﬁcacy of anti-
inﬂammatories in humans and to assess the mechanisms
responsible for steroid insensitivity in vivo. As the model is
relatively simple, robust and of reasonable throughput we
also feel it can be a platform for the exploration of other
factors involved in smoke-induced inﬂammation, for exam-
ple, the addition of virus or bacteria to TS-induced
inﬂammation [6]. We have explored the role of the CCR1
receptor in TS-induced inﬂammation and we ﬁnd that abla-
tionofthisgenesigniﬁcantlyreducesTS-drivenneutrophilia.
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